Insulin is a well-characterized peptide that can be produced byrecombinant听DNA technology for听human听therapeutic use.
The global Recombinant Human Insulin market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Recombinant Human Insulin is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Recombinant Human Insulin is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Recombinant Human Insulin is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key manufacturers of Recombinant Human Insulin include Akron Biotech, Wockhardt, Dance Biopharm, Novo Nordisk, Gan & Lee, United Laboratories and Dongbro Pharmaceuticri, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Report Covers:
This report presents an overview of global market for Recombinant Human Insulin, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Recombinant Human Insulin, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Recombinant Human Insulin, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Recombinant Human Insulin sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Recombinant Human Insulin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Recombinant Human Insulin sales, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Dance Biopharm
Novo Nordisk
Gan & Lee
United Laboratories
Dongbro Pharmaceuticri
Segment by Type
by Recombinant DNA Technology Using Fermentation in Bacteria Way
by Recombinant DNA Technology Using Fermentation in Yeast Way
Segment by Application
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Recombinant Human Insulin in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Recombinant Human Insulin manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant Human Insulin sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Study Coverage
1.1 Recombinant Human Insulin Product Introduction
1.2 Market by Type
1.2.1 Global Recombinant Human Insulin Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 by Recombinant DNA Technology Using Fermentation in Bacteria Way
1.2.3 by Recombinant DNA Technology Using Fermentation in Yeast Way
1.3 Market by Application
1.3.1 Global Recombinant Human Insulin Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Type 1 Diabetes Mellitus
1.3.3 Type 2 Diabetes Mellitus
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Recombinant Human Insulin Sales Estimates and Forecasts 2019-2030
2.2 Global Recombinant Human Insulin Revenue by Region
2.2.1 Global Recombinant Human Insulin Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Recombinant Human Insulin Revenue by Region (2019-2024)
2.2.3 Global Recombinant Human Insulin Revenue by Region (2025-2030)
2.2.4 Global Recombinant Human Insulin Revenue Market Share by Region (2019-2030)
2.3 Global Recombinant Human Insulin Sales Estimates and Forecasts 2019-2030
2.4 Global Recombinant Human Insulin Sales by Region
2.4.1 Global Recombinant Human Insulin Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Recombinant Human Insulin Sales by Region (2019-2024)
2.4.3 Global Recombinant Human Insulin Sales by Region (2025-2030)
2.4.4 Global Recombinant Human Insulin Sales Market Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Recombinant Human Insulin Sales by Manufacturers
3.1.1 Global Recombinant Human Insulin Sales by Manufacturers (2019-2024)
3.1.2 Global Recombinant Human Insulin Sales Market Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Recombinant Human Insulin in 2023
3.2 Global Recombinant Human Insulin Revenue by Manufacturers
3.2.1 Global Recombinant Human Insulin Revenue by Manufacturers (2019-2024)
3.2.2 Global Recombinant Human Insulin Revenue Market Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Recombinant Human Insulin Revenue in 2023
3.3 Global Key Players of Recombinant Human Insulin, Industry Ranking, 2022 VS 2023 VS 2024
3.4 Global Recombinant Human Insulin Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Recombinant Human Insulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Recombinant Human Insulin, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Recombinant Human Insulin, Product Offered and Application
3.8 Global Key Manufacturers of Recombinant Human Insulin, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Recombinant Human Insulin Sales by Type
4.1.1 Global Recombinant Human Insulin Historical Sales by Type (2019-2024)
4.1.2 Global Recombinant Human Insulin Forecasted Sales by Type (2025-2030)
4.1.3 Global Recombinant Human Insulin Sales Market Share by Type (2019-2030)
4.2 Global Recombinant Human Insulin Revenue by Type
4.2.1 Global Recombinant Human Insulin Historical Revenue by Type (2019-2024)
4.2.2 Global Recombinant Human Insulin Forecasted Revenue by Type (2025-2030)
4.2.3 Global Recombinant Human Insulin Revenue Market Share by Type (2019-2030)
4.3 Global Recombinant Human Insulin Price by Type
4.3.1 Global Recombinant Human Insulin Price by Type (2019-2024)
4.3.2 Global Recombinant Human Insulin Price Forecast by Type (2025-2030)
5 Market Size by Application
5.1 Global Recombinant Human Insulin Sales by Application
5.1.1 Global Recombinant Human Insulin Historical Sales by Application (2019-2024)
5.1.2 Global Recombinant Human Insulin Forecasted Sales by Application (2025-2030)
5.1.3 Global Recombinant Human Insulin Sales Market Share by Application (2019-2030)
5.2 Global Recombinant Human Insulin Revenue by Application
5.2.1 Global Recombinant Human Insulin Historical Revenue by Application (2019-2024)
5.2.2 Global Recombinant Human Insulin Forecasted Revenue by Application (2025-2030)
5.2.3 Global Recombinant Human Insulin Revenue Market Share by Application (2019-2030)
5.3 Global Recombinant Human Insulin Price by Application
5.3.1 Global Recombinant Human Insulin Price by Application (2019-2024)
5.3.2 Global Recombinant Human Insulin Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Recombinant Human Insulin Market Size by Type
6.1.1 US & Canada Recombinant Human Insulin Sales by Type (2019-2030)
6.1.2 US & Canada Recombinant Human Insulin Revenue by Type (2019-2030)
6.2 US & Canada Recombinant Human Insulin Market Size by Application
6.2.1 US & Canada Recombinant Human Insulin Sales by Application (2019-2030)
6.2.2 US & Canada Recombinant Human Insulin Revenue by Application (2019-2030)
6.3 US & Canada Recombinant Human Insulin Market Size by Country
6.3.1 US & Canada Recombinant Human Insulin Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Recombinant Human Insulin Sales by Country (2019-2030)
6.3.3 US & Canada Recombinant Human Insulin Revenue by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Recombinant Human Insulin Market Size by Type
7.1.1 Europe Recombinant Human Insulin Sales by Type (2019-2030)
7.1.2 Europe Recombinant Human Insulin Revenue by Type (2019-2030)
7.2 Europe Recombinant Human Insulin Market Size by Application
7.2.1 Europe Recombinant Human Insulin Sales by Application (2019-2030)
7.2.2 Europe Recombinant Human Insulin Revenue by Application (2019-2030)
7.3 Europe Recombinant Human Insulin Market Size by Country
7.3.1 Europe Recombinant Human Insulin Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Recombinant Human Insulin Sales by Country (2019-2030)
7.3.3 Europe Recombinant Human Insulin Revenue by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Recombinant Human Insulin Market Size
8.1.1 China Recombinant Human Insulin Sales (2019-2030)
8.1.2 China Recombinant Human Insulin Revenue (2019-2030)
8.2 China Recombinant Human Insulin Market Size by Application
8.2.1 China Recombinant Human Insulin Sales by Application (2019-2030)
8.2.2 China Recombinant Human Insulin Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Recombinant Human Insulin Market Size by Type
9.1.1 Asia Recombinant Human Insulin Sales by Type (2019-2030)
9.1.2 Asia Recombinant Human Insulin Revenue by Type (2019-2030)
9.2 Asia Recombinant Human Insulin Market Size by Application
9.2.1 Asia Recombinant Human Insulin Sales by Application (2019-2030)
9.2.2 Asia Recombinant Human Insulin Revenue by Application (2019-2030)
9.3 Asia Recombinant Human Insulin Sales by Region
9.3.1 Asia Recombinant Human Insulin Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Recombinant Human Insulin Revenue by Region (2019-2030)
9.3.3 Asia Recombinant Human Insulin Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Recombinant Human Insulin Market Size by Type
10.1.1 Middle East, Africa and Latin America Recombinant Human Insulin Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Recombinant Human Insulin Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Recombinant Human Insulin Market Size by Application
10.2.1 Middle East, Africa and Latin America Recombinant Human Insulin Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Recombinant Human Insulin Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Recombinant Human Insulin Sales by Country
10.3.1 Middle East, Africa and Latin America Recombinant Human Insulin Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Recombinant Human Insulin Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Recombinant Human Insulin Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Akron Biotech
11.1.1 Akron Biotech Company Information
11.1.2 Akron Biotech Overview
11.1.3 Akron Biotech Recombinant Human Insulin Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 Akron Biotech Recombinant Human Insulin Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Akron Biotech Recent Developments
11.2 Wockhardt
11.2.1 Wockhardt Company Information
11.2.2 Wockhardt Overview
11.2.3 Wockhardt Recombinant Human Insulin Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 Wockhardt Recombinant Human Insulin Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Wockhardt Recent Developments
11.3 Dance Biopharm
11.3.1 Dance Biopharm Company Information
11.3.2 Dance Biopharm Overview
11.3.3 Dance Biopharm Recombinant Human Insulin Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 Dance Biopharm Recombinant Human Insulin Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Dance Biopharm Recent Developments
11.4 Novo Nordisk
11.4.1 Novo Nordisk Company Information
11.4.2 Novo Nordisk Overview
11.4.3 Novo Nordisk Recombinant Human Insulin Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 Novo Nordisk Recombinant Human Insulin Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Novo Nordisk Recent Developments
11.5 Gan & Lee
11.5.1 Gan & Lee Company Information
11.5.2 Gan & Lee Overview
11.5.3 Gan & Lee Recombinant Human Insulin Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 Gan & Lee Recombinant Human Insulin Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Gan & Lee Recent Developments
11.6 United Laboratories
11.6.1 United Laboratories Company Information
11.6.2 United Laboratories Overview
11.6.3 United Laboratories Recombinant Human Insulin Sales, Price, Revenue and Gross Margin (2019-2024)
11.6.4 United Laboratories Recombinant Human Insulin Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 United Laboratories Recent Developments
11.7 Dongbro Pharmaceuticri
11.7.1 Dongbro Pharmaceuticri Company Information
11.7.2 Dongbro Pharmaceuticri Overview
11.7.3 Dongbro Pharmaceuticri Recombinant Human Insulin Sales, Price, Revenue and Gross Margin (2019-2024)
11.7.4 Dongbro Pharmaceuticri Recombinant Human Insulin Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Dongbro Pharmaceuticri Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Recombinant Human Insulin Industry Chain Analysis
12.2 Recombinant Human Insulin Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Recombinant Human Insulin Production Mode & Process
12.4 Recombinant Human Insulin Sales and Marketing
12.4.1 Recombinant Human Insulin Sales Channels
12.4.2 Recombinant Human Insulin Distributors
12.5 Recombinant Human Insulin Customers
13 Market Dynamics
13.1 Recombinant Human Insulin Industry Trends
13.2 Recombinant Human Insulin Market Drivers
13.3 Recombinant Human Insulin Market Challenges
13.4 Recombinant Human Insulin Market Restraints
14 Key Findings in The Global Recombinant Human Insulin Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Akron Biotech
Wockhardt
Dance Biopharm
Novo Nordisk
Gan & Lee
United Laboratories
Dongbro Pharmaceuticri
听
听
*If Applicable.